衞寧健康(300253.SZ)2019年度淨利升31.36%至3.98億元 擬10轉3派0.25元
格隆匯4月3日丨衞寧健康(300253.SZ)發佈2019年年度報告，營業收入19.08億元，同比增長32.61%；歸屬於上市公司股東的淨利潤3.98億元，同比增長31.36%；歸屬於上市公司股東的扣除非經常性損益的淨利潤3.42億元，同比增長22.59%；基本每股收益0.2463元；擬每10股轉增3股派發現金紅利0.25元(含税)。
報告期內，公司核心產品軟件銷售及技術服務業務收入(合計佔營業收入的比重為75.57%，上年同期為77.95%)同比增長28.57%(上年同比增長31.92%，2018-2019年均複合增長30.23%)；硬件銷售業務收入(佔營業收入的比重為23.61%，上年同期為21.13%)同比增長48.18%(上年同比增長-13.81%，因此顯得本年增長很明顯，2018-2019年均複合增長13.01%)。
另外，公司在報告期內繼續加大市場拓展，提升管理水平和經營質量，使得本年度業務訂單持續保持上年的快速增長趨勢，其中新增中標1000萬元以上項目41個(上年同期為24個)，預收款項餘額為1.77億元(2018年同期為2.05億元，2017年同期為9630.87萬元)，因上年預收款項同比高速增長提高了基數，使得本年預收款項同比增長-13.87%(上年同比增長112.78%，因此顯得本年為負增長，2018-2019年均複合增長35.38%)；經營活動產生的現金流量淨額為2.33億元(2018年同期為1.24億元，2017年同期為7978.72萬元)，同比增長88.31%(上年同比增長55.28%，2018-2019年均複合增長71.00%)；資本化研發支出佔研發投入比重下降為46.72%(上年同期為49.40%)，資本化研發支出佔當期淨利潤的比重下降為45.59%(上年同期為46.84%)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
